Tel Aviv Sourasky Medical Center-ko ikertzaileekin lankidetzan egindako argitalpenak (16)

2023

  1. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

    New England Journal of Medicine, Vol. 389, Núm. 4, pp. 335-347

  2. Clinical outcomes by supplemental oxygen use in remdesivir-treated, hospitalised adults with COVID-19

    Infectious Diseases Now, Vol. 53, Núm. 7

  3. Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial

    Annals of Oncology, Vol. 34, Núm. 10, pp. 885-898

2021

  1. Motixafortide and pembrolizumab combined to nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic cancer: The COMBAT/ KEYNOTE-202 trial

    Clinical Cancer Research, Vol. 27, Núm. 18, pp. 5020-5027

2019

  1. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

    The Lancet Haematology, Vol. 6, Núm. 9, pp. e459-e469

  2. Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: A European Scleroderma Trials and Research (EUSTAR) analysis

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 9, pp. 1242-1248

  3. Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the european scleroderma trials and research (eustar) cohort

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 5, pp. 648-656

2018

  1. Risk factors for unfavourable postoperative outcome in patients with Crohn's disease undergoing right hemicolectomy or ileocaecal resection. An international audit by ESCP and S-ECCO

    Colorectal Disease, Vol. 20, Núm. 3, pp. 219-227

2017

  1. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

    Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380

2016

  1. A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae

    Mayo Clinic Proceedings, Vol. 91, Núm. 10, pp. 1362-1371

2015

  1. Adjuvant bisphosphonate treatment in early breast cancer: Meta-analyses of individual patient data from randomised trials

    The Lancet, Vol. 386, Núm. 10001, pp. 1353-1361

2011

  1. Erratum: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: A consensus statement (Annals of Surgical Oncology 14 (128-133)DOI: 10.1245/s10434-006-9185-7)

    Annals of Surgical Oncology

2010

  1. Correction: Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: A randomized controlled trial [Respiratory Research, 11, (2010):(10)], DOI: 10.1186/1465-9921-11-10

    Respiratory Research

2009

  1. Consensus Guidance for Banking and Supply of Human Embryonic Stem Cell Lines for Research Purposes

    STEM CELL REVIEWS AND REPORTS, Vol. 5, Núm. 4, pp. 301-314

2007

  1. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: A consensus statement

    Annals of Surgical Oncology, Vol. 14, Núm. 1, pp. 128-133

2003

  1. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow

    Blood, Vol. 102, Núm. 8, pp. 3043-3051